Current Neuro-Oncology

Volume 28 Number 7
10 March 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 7, 10 March

López-Rueda A, Pons A, Majos C, Chirife O, Cos M.
Eligibility assessment for yttrium-90 radioembolisation in patients with recurrent glioblastoma: A single-centre cohort study based on the FRONTIER clinical trial criteria (NCT05303467).
Radiologia (Engl Ed). 2026 Mar 2;68(2):501691. doi: 10.1016/j.rxeng.2026.501691. PMID: 41819978˰ ˍ

Tlais D, Zhang Q, Roach JT, Tinkle CL, Lin T, Li X, Mostafa A, Moreira DC, McNall-Knapp RY, Rush SZ, Le BH, Sinno S, Ramnarayan A, Ginn KF, Partap S, Onar-Thomas A, Furtado LV, Bag AK, Chiang J.
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Acta Neuropathol. 2026 Mar 2;151(1):22. doi: 10.1007/s00401-026-02992-w. PMID: 41770225. ˍ

Bertalan G, Hainc N, Paignon G, Todea RA, Bink A, Weiss T, Weller M, Serra C, Kulcsar Z.
Three-Dimensional quantitative analysis of the Peri-Enhancing zone reveals ADC and CBV signatures of glioblastoma recurrence.
Neuroimage Clin. 2026 Mar 4;49:103977. doi: 10.1016/j.nicl.2026.103977. PMID: 41791182. ˍ

Li T, Zhou T, Wang B, Tao Z, Zhao M, Wang L, Jin J, Zhao Y, Gong C, Cao J, Miao H, Peng W, Wang J, Jin M, Hu X, Zhang J.
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
J Clin Oncol. 2026 Mar 4:JCO2502021. doi: 10.1200/JCO-25-02021. PMID: 41779972. Trial registration ID: NCT04303988. ˍ

Li Y, Wang J, Zhang Z, Fan X, Wang Y, Ma W, Jiang T, Fang S.
Functional gradient analysis reveals potential therapeutic mechanisms of nrTMS for postoperative motor deficits in glioma patients: A randomized controlled trial.
Neuroimage Clin. 2026 Mar 4;50:103981. doi: 10.1016/j.nicl.2026.103981. PMID: 41812281. Trial registration ID: NCT05803057. ˍ

Del Valle MM, Colon EM, Kettimuthu K, Maner-Smith K, Olson JJ, Kucheryavykh LY.
Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas.
Cancer Chemother Pharmacol. 2026 Mar 6;96(1):22. doi: 10.1007/s00280-026-04870-4. PMID: 41790275. Trial registration ID: NCT05798507. ˍ

Pandey A, Datta A, Verma R, Jaiswal AK, Kumar R, Das KK, Baishya B.
Exploring metabolic signatures in urine using NMR for improved prognosis of gliomas.
Metabolomics. 2026 Mar 6;22(2):32. doi: 10.1007/s11306-026-02414-8. PMID: 41790324. ˍ

Yindeedej V, Phairintr P, Rukskul P.
Bilateral Hippocampal High-Grade Glioma: An Exceptional Rare Entity.
World Neurosurg. 2026 Mar 6;209:124896. doi: 10.1016/j.wneu.2026.124896. PMID: 41796677. ˍ

Giordano A, Graham N, Aizer AA, Tayob N, Pereslete AM, Schoenfeld JD, Leone JP, Davis R, Erick TK, Mayer EL, Winer EP, Krop I, Tolaney SM, Lin NU.
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.
Breast Cancer Res Treat. 2026 Mar 7;216(2):24. doi: 10.1007/s10549-026-07932-6. PMID: 41793510. Trial registration ID: NCT03483012. ˍ

Crowell C, Mankuzhy NP, Bennett J, Bandopadhayay P, Sturm D, Green AL, Gupta T, Chatterjee A, Epari S, Chinnaswamy G, Prasad M, Patel SH, MacNeil M, Vanan MI, Larouche V, Renzi S, Jones J, Perreault S, Mata-Mbemba D, Sangatsuda Y, Yoshimoto K, Lin E, Feddersen C, Cruz O, Pavon-Mengual M, Vizzini O, Zápotocký M, Popovacki A, Klawinski D, Hansford JR, Schlosser MP, Omene E, Alexander KL, Satgunaseelan L, Williams A, Yao K, Ronsley R, Cheng S, Ludlow L, Eisenstat D, Khuong-Quang DA, Tabouret E, André N, Matheson K, Chan A, Lim-Fat MJ, Lapointe S, Cayrol R, Coleman C, Juretic N, McThenia S, Khan S, Wright-Nadkarni M, Salloum R, Galvin RT, Sener U, Hawkins C, Imber BS, Karajannis MA, Jones DTW, Ligon KL, Jabado N, Erker C.
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study.
Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-3764. PMID: 41801141. ˍ

Gutiérrez-González R, Herrero Z, Rodriguez-Rubio E, Zamarron A.
Survival and prediction of distant recurrence in glioblastoma.
Neurol Neurochir Pol. 2026 Mar 9. doi: 10.5603/pjnns.108958. PMID: 41801153. ˍ

...

Garcilazo-Reyes Y, Dal Col P, Bielle F, Mokhtari K, Feuvret L, Jacob J, Duran-Peña A, Capelle L, Savatovsky J, Bourdeaut F, Masliah-Planchon J, Cacho-Díaz B, Hoang-Xuan K, Idbaih A, Laigle-Donadey F.
Prognostic factors in adult patients with medulloblastoma.
Neurooncol Pract. 2025 Sep 1;13(1):112-125. doi: 10.1093/nop/npaf084. PMID: 41798122˰ ˍ

Xiao G, Ye Q.
The evolving burden of pediatric solid tumors: A global analysis from 1990 to 2021.
Indian J Cancer. 2025 Oct 1;62(4):493-512. doi: 10.4103/ijc.ijc_82_25. PMID: 41797586. ˍ

Lachance DH, Decker PA, Kollmeyer TM, Drucker KL, Praska CE, Kosel ML, Odukoya AA, Kizilbash SH, Maqbool MA, Shafqat S, Tobin WO, Parney IF, Burns TC, Galanis E, Giannini C, Vaubel RA, Ida CM, Jenkins RB, Eckel-Passow JE.
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH-wildtype.
Neurooncol Adv. 2025 Dec 17;8(1):vdaf260. doi: 10.1093/noajnl/vdaf260. PMID: 41908146 ˍ

Furman O, Falah E, Dvir I, Satra-Shenes O, Bittan A, Bokstein F, Blumenthal DT, Taliansky A, Zach L.
Rethinking treatment de-escalation in elderly glioblastoma: Lessons from a multicenter real-world cohort.
Neurooncol Adv. 2026 Jan 27;8(1):vdag014. doi: 10.1093/noajnl/vdag014. PMID: 41778155 ˍ

Del Bene M, Caldiera V, Stanziano M, Carone G, Falanga A, Piccardi A, Simonetti G, Carozzi C, Frazzetta G, Silvani A, Prada F, Grisoli M, Ciceri E, DiMeco F.
Focused ultrasound for blood-brain barrier opening in brain tumor patients: Technical nuances.
Neurooncol Adv. 2026 Jan 31;8(1):vdag020. doi: 10.1093/noajnl/vdag020. PMID: 41821761. ˍ

Tao R, Guo Y, Zhang Y, Li W, Yang P, Zhou D.
A comprehensive single-cell analysis reveals the impact of laser interstitial thermal therapy on the tumor microenvironment in glioblastoma.
J Immunol. 2026 Feb 9;215(2):vkaf327. doi: 10.1093/jimmun/vkaf327. PMID: 41764740˰ ˍ

Hata N, Otsuji R, Kuga D, Fujioka Y, Sangatsuda Y, Hatae R, Fudaba H, Momii Y, Mizoguchi M, Fujiki M, Yoshimoto K.
Long-term outcome of nimustine-based chemotherapy for oligodendroglioma.
Neurooncol Adv. 2026 Feb 12;8(1):vdag025. doi: 10.1093/noajnl/vdag025. PMID: 41890358. ˍ

Maio V, Shah R, Lin M, J Moeller P, Alnahhas I, Hass R, Shi W, Keith SW.
Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study.
Neurooncol Adv. 2026 Feb 16;8(1):vdag041. doi: 10.1093/noajnl/vdag041. PMID: 41788737. ˍ

Wang D, Zhang J, Liu G, Bu C, Wei S, Li M, Lv G, Sheng Z, Mei J, Yan Z, Gao Y, Zhao R, Shi Y, Wang M, Bu X.
Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis.
Neurooncol Adv. 2026 Feb 16;8(1):vdag040. doi: 10.1093/noajnl/vdag040. PMID: 41778154. ˍ

Abouelleil M, Nabulsi O, Hamidi S, Chandra A, Massie L, Mansour T, Mustaquim M, Macki M, Walbert T, Robin A, Griffith B, Jamaluddin B, Chang V, Kalkanis SN, Lee IY, Zakaria HM.
Temporalis Muscle Thickness as a Prognostic Factor for 30-Day, 90-Day, and Overall Mortality in Newly Diagnosed Glioblastoma.
Cureus. 2026 Feb 19;18(2):e103895. doi: 10.7759/cureus.103895. PMID: 41869180. ˍ

Rizzuto I, Ieni A, Scarcella SC, Sciacca V, Fiorentino V, Napoli C, Martini M, Germanò A, Granata F, Pergolizzi S, Tuccari G.
Gliosarcoma: A Reappraisal of Neuroradiological, Surgical, Morphological, and Radiotherapeutic Characteristics of a Cohort From South Italy Single-Center.
Anal Cell Pathol (Amst). 2026 Feb 23;2026(1):e4966984. doi: 10.1155/ancp/4966984. PMID: 41810935. ˍ